Home › Trial NCT04134182
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
- Trial IDNCT04134182
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorKidney Cancer Research Bureau
- Enrollment8
- Start date2019-10-16
- ConditionsRenal Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.